SAB Biotherapeutics, Inc. (SABS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US78397T2024
SAB Biotherapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -48.95 m USD |
| EBIT | 13.51 m USD |
| Net income | 13.27 m USD |
| Diluted EPS – continuing operations | -0.79 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
More stocks
- Lineage Cell Therapeutics, Inc. (LCTX)
- Tehmag Foods (1264.TWO)
- Boen Group Co. Ltd. Cl A (001366.SZ)
- Envitec Biogas (ETG.DE)
- Promotora Ambiental S.A.B. de C.V (PASAB.MX)
- H&R GmbH & Co KgaA (2HRA.DE)
- Pizza Pizza Royalty Corp. (PZA.TO)
- FIRST NORTHERN COMMUNITY BANCORP (FNRN)
- Track & Field Co S.A (TFCO4.SA)
- Profile Systems & Software SA (PROF.AT)
- Bauer (B5A0.HM)
- Gurit Holding AG (GURN.SW)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.